Aktuelle News

Bleiben Sie informiert über aktuelle Entwicklungen und Neuigkeiten bei der SMOB. Hier finden Sie regelmäßige Updates zu spannenden Themen und wichtigen Ereignissen, die unsere Fachgesellschaft betreffen.

SMOB recommendations for prioritization of 2.4 mg Semaglutide therapy 

By 19 Jun, 2024 Allgemein

Bernd Schultes1, Marco Bueter2,3, Lucie Favre4,5,6, Katharina Timper7,8 for the collaborative task force “prioritization of anti-obesity pharmacotherapy” of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB) Background The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product Wegovy® (2.4 mg semaglutide) demands a prioritization by means of which […]

More

SMOB statement for the world obesity day 2024

By 11 Apr, 2024 Allgemein

To our Patients,To the loved ones of people living with obesity,To our Colleagues in healthcare, Obesity care has seen considerable improvements in the past years. Pharmacotherapy and bariatric-metabolic surgery can now offer several treatment options that are secure and efficient.However, as it often happens when medical progress evolves fast, good practice recommendations and treatments with […]

More